Legend Biotech (LEGN)
(Delayed Data from NSDQ)
$58.93 USD
+0.19 (0.32%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $58.99 +0.06 (0.10%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Legend Biotech Corporation Sponsored ADR (LEGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$82.95 | $95.00 | $60.00 | 41.22% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Legend Biotech Corporation Sponsored ADR comes to $82.95. The forecasts range from a low of $60.00 to a high of $95.00. The average price target represents an increase of 41.22% from the last closing price of $58.74.
Analyst Price Targets (18)
Broker Rating
Legend Biotech Corporation Sponsored ADR currently has an average brokerage recommendation (ABR) of 1.30 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on 20 recommendations.
Of the 20 recommendations deriving the current ABR, 16 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 80% and 10% of all recommendations. A month ago, Strong Buy made up 80%, while Buy represented 10%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LEGN.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 16 | 16 | 16 | 15 | 14 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.30 | 1.30 | 1.30 | 1.32 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/18/2024 | Scotiabank | George Farmer | Strong Buy | Strong Buy |
7/17/2024 | Raymond James | Sean Mccutcheon | Moderate Buy | Moderate Buy |
7/15/2024 | Cowen & Co. | Yaron Werber | Strong Buy | Strong Buy |
7/3/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
6/21/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
6/17/2024 | Truist Securities | Asthika S Goonewardene | Not Available | Strong Buy |
5/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/9/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Strong Buy | Strong Buy |
4/8/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Rick Bienkowski | Not Available | Strong Buy |
3/27/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/18/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
2/23/2024 | William Blair | Sami Corwin | Hold | Hold |
1/24/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/7/2024 | BTIG | Justin R Zelin | Strong Buy | Strong Buy |
1/2/2024 | Guggenheim Securities | Michael Schmidt | Hold | Hold |
11/6/2023 | Goldman Sachs | Ziyi Chen | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.30 |
ABR (Last week) | 1.30 |
# of Recs in ABR | 20 |
Average Target Price | $82.95 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -0.54 |